Biogen’s shares dropped sharply on Friday after the FDA sought an independent assessment of the process that led to the company’s recent Alzheimer’s approval./n
Read MoreBiogen Stock Drags On Alzheimer’s Players As FDA Requests Review Of Aduhelm Approval
2021-07-09T20:46:26-04:00July 9th, 2021|
Related Posts
-
The 3 Best Penny Stocks to Buy in May 2024
May 19th, 2024